Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

6.000 -0.110 (-1.80%)
Streaming Delayed Price Updated: 1:20 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
Decoding 4 Analyst Evaluations For Altimmune
Via Benzinga
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. 
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in August 2024
Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10. 
Via InvestorPlace
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
ALT Stock Earnings: Altimmune Misses EPS for Q2 2024
ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Forecasting The Future: 5 Analyst Projections For Altimmune
Via Benzinga
How Is The Market Feeling About Altimmune?
Via Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
3 Undervalued Biotech Stocks With Breakout Potential
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
Via InvestorPlace
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on. 
Via InvestorPlace
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Both competitors have promising lead programs, and enough cash, too. 
Via The Motley Fool
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases. 
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
While their share prices have traveled different paths recently, the similarity between the two companies is striking. 
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
The market for weight loss medicines keeps getting hotter and hotter. 
Via The Motley Fool
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. 
Via InvestorPlace
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's Chief Financial Officer. 
Via Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
Via InvestorPlace
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms
Bitfarms stock is down on Monday after Riot Platforms withdrew its offer for BITF stock in favor of nominating new board memebers. 
Via InvestorPlace
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today. 
Via InvestorPlace
Altimmune Stock Is Rising Monday: What's Driving The Action?
Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes... 
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
3 Stocks Under $10 Set to Quadruple by 2025: June Edition
Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst. 
Via InvestorPlace
3 Stocks Quietly Preparing for a 10X Surge: June Edition
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop
Overlooked penny stocks are the path to outsized gains and these shares seem to fit the bill at the moment. 
Via InvestorPlace
3 Monster Stocks in the Making You Can Buy Right Now
These stocks might not be small for too much longer. 
Via The Motley Fool
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.